top of page

Jardiance reduces risk of progressive kidney disease in type 2 diabetes

New data showed Jardiance (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in adults with type 2 diabetes with established cardiovascular disease.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page